The efficacy and toxicity of individualized intensity-modulated radiotherapy based on the tumor extension patterns of nasopharyngeal carcinoma

被引:18
|
作者
Lin, Li [1 ]
Yao, Ji-Jin [1 ]
Zhou, Guan-Qun [1 ]
Guo, Rui [1 ]
Zhang, Fan [1 ]
Zhang, Yuan [1 ]
Xu, Lin [1 ]
Zhang, Lu-Lu [1 ]
Lin, Ai-Hua [2 ]
Ma, Jun [1 ]
Sun, Ying [1 ]
机构
[1] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc,Dept Radiat Oncol, Guangzhou 510060, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sch Publ Hlth, Dept Med Stat & Epidemiol, Guangzhou 510080, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
nasopharyngeal carcinoma; intensity modulated radiotherapy; individualized clinical target volume; clinical outcome; toxicities; CONVENTIONAL 2-DIMENSIONAL RADIOTHERAPY; RADIATION-THERAPY; TREATMENT OUTCOMES; NECK IRRADIATION; CANCER; DELINEATION; SURVIVAL; DISEASE; PATIENT; UPDATE;
D O I
10.18632/oncotarget.8004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To evaluate the efficacy and toxicity of intensity-modulated radiotherapy (IMRT) using individualized clinical target volumes (CTVs) based on the loco-regional extension patterns of nasopharyngeal carcinoma (NPC). Methods: From December 2009 to February 2012, 220 patients with histologically-proven, non-disseminated NPC were prospectively treated with IMRT according to an individualized delineation protocol. CTV1 encompassed the gross tumor volume, entire nasopharyngeal mucosa and structures within the pharyngobasilar fascia with a margin. CTV2 encompassed bilateral high risk anatomic sites and downstream anatomic sites adjacent to primary tumor, bilateral retropharyngeal regions, levels II, III and Va, and prophylactic irradiation was gave to one or two levels beyond clinical lymph nodes involvement. Clinical outcomes and toxicities were evaluated. Results: Median follow-up was 50.8(range, 1.3-68.0) months, four-year local relapse-free, regional relapse-free, distant metastasis-free, disease-free and overall survival rates were 94.7%, 97.0%, 91.7%, 87.2% and 91.9%, respectively. Acute severe (>= grade 3) mucositis, dermatitis and xerostomia were observed in 27.6%, 3.6% and zero patients, respectively. At 1 year, xerostomia was mild, with frequencies of Grade 0, 1, 2 and 3 xerostomia of 27.9%, 63.3%, 8.3% and 0.5%, respectively. Conclusions: IMRT using individualized CTVs provided high rates of local and regional control and a favorable toxicity profile in NPC. Individualized CTV delineation strategy is a promising one that may effectively avoid unnecessary or missed irradiation, and deserve optimization to define more precise individualized CTVs.
引用
收藏
页码:20680 / 20690
页数:11
相关论文
共 50 条
  • [21] Tumor Regression and Patterns of Distant Metastasis of T1-T2 Nasopharyngeal Carcinoma with Intensity-Modulated Radiotherapy
    Wu, Ming-Yao
    He, Xia-Yun
    Hu, Chao-Su
    PLOS ONE, 2016, 11 (04):
  • [22] Patterns of Local-Regional Relapse Following Intensity-Modulated Radiotherapy for Patients With Nasopharyngeal Carcinoma
    Liu, X.
    Wu, B.
    Huang, J.
    Ding, Q.
    Qin, Y.
    Hong, X.
    Shi, L.
    Zhang, Z.
    Peng, G.
    Yang, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E387 - E388
  • [23] Clinical characteristics and patterns of failure in the parotid region after intensity-modulated radiotherapy for nasopharyngeal carcinoma
    Cao, Cai-neng
    Luo, Jing-wei
    Gao, Li
    Yi, Jun-lin
    Huang, Xiao-dong
    Wang, Kai
    Zhang, Shi-ping
    Qu, Yuan
    Li, Su-yan
    Cai, Wei-ming
    Xiao, Jian-ping
    Zhang, Zhong
    Xu, Guo-zhen
    ORAL ONCOLOGY, 2013, 49 (06) : 611 - 614
  • [24] Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma
    Liao, Shufang
    Zhang, Bin
    Su, Yixin
    Pan, Yufei
    Zhang, Jian
    Ye, Zhenkai
    Zhang, Rongjun
    Kong, Xiangyun
    Qin, Guanjie
    Mo, Yunyan
    Ruan, Xiaolan
    Liu, Jian
    Gan, Chunqiao
    Dai, Jinxuan
    Zhang, Ruyun
    Luo, Guanhong
    Liao, Xiaofei
    Jiang, Wei
    STRAHLENTHERAPIE UND ONKOLOGIE, 2024, 200 (10) : 867 - 875
  • [25] Tumor factors associated with in-field failure for nasopharyngeal carcinoma after intensity-modulated radiotherapy
    Liu, Xixi
    Wu, Bian
    Huang, Jing
    Qin, You
    Zhang, Zhanjie
    Shi, Liangliang
    Hong, Xiaohua
    Ding, Qian
    Peng, Gang
    Yang, Kunyu
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2022, 44 (04): : 876 - 888
  • [26] Prognostic value of total tumor volume in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy
    Shao-Bo Liang
    Jian-Jian Teng
    Xue-Feng Hu
    Xing-Li Yang
    Min Luo
    Xiao-Na Fang
    Dong-Sheng Liu
    Yong Chen
    Li-Wu Fu
    BMC Cancer, 17
  • [27] Prognostic value of total tumor volume in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy
    Liang, Shao-Bo
    Teng, Jian-Jian
    Hu, Xue-Feng
    Yang, Xing-Li
    Luo, Min
    Fang, Xiao-Na
    Liu, Dong-Sheng
    Chen, Yong
    Fu, Li-Wu
    BMC CANCER, 2017, 17
  • [28] PROGNOSTIC VALUE OF PREVERTEBRAL SPACE INVOLVEMENT IN NASOPHARYNGEAL CARCINOMA BASED ON INTENSITY-MODULATED RADIOTHERAPY
    Zhou, Guan-qun
    Mao, Yan-Ping
    Chen, Lei
    Li, Wen-Fei
    Liu, Li-Zhi
    Sun, Ying
    Chen, Yong
    Tian, Li
    Lin, Ai-Hua
    Li, Li
    Ma, Jun
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (03): : 1090 - 1097
  • [29] Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: The Hong Kong experience
    Kam, MKM
    Teo, PML
    Chau, RMC
    Cheung, KY
    Choi, PHK
    Kwan, WH
    Leung, SF
    Zee, B
    Chan, ATC
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (05): : 1440 - 1450
  • [30] Paranasal Sinus Invasion in Nasopharyngeal Carcinoma after Intensity-Modulated Radiotherapy
    Cao, Caineng
    Jiang, Feng
    Jin, Qifeng
    Jin, Ting
    Huang, Shuang
    Hu, Qiaoying
    Chen, Yuanyuan
    Piao, Yongfeng
    Hua, Yonghong
    Feng, Xinglai
    Chen, Xiaozhong
    CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 73 - 79